Europe Too: Approval Of A Higher Dose Glatiramer Generic
Executive Summary
Like in the US, Teva's more convenient three-times-a-week dosage form of Copaxone is now facing competition in Europe from a generic, in this case one developed by the Netherlands' Synthon and Iceland's Alvogen.
You may also be interested in...
EPO Reversal Overturns Copaxone 40mg Patent
Mylan has celebrated a reversal from the European Patent Office that has seen a key patent protecting Teva’s higher-strength 40mg/ml thrice-weekly version of Copaxone deemed invalid and revoked across Europe. Meanwhile, Teva has commented on the possibility of an appeal.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.